NCT07444619招募中1 期
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Safety and Adverse Events (AEs)
研究概览
简要总结
The goal of this study is to build on the experience of the SAINT trial by evaluating the safety and efficacy of the addition of pazopanib to their published chemotherapy regimen.
详细描述
Primary Objectives:
- To determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of Pazopanib in combination with Trabectedin, Ipilimumab and Nivolumab.
- To determine the safety and tolerance of Pazopanib when given in conjunction with Trabectedin, Ipilimumab and Nivolumab in pediatric and young adult patients with Recurrent STS.
Secondary Objective:
• To observe and record disease response (anti-tumor activity). Although the clinical benefit of the combination (Pazopanib when given in conjunction with Trabectedin, Ipilimumab and Nivolumab) has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief. Outcomes for disease response include Best OverallResponse (BOR), Duration of Response (DOR), and Progression-Free Survival (PFS) will be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All Recurrent STS are eligible for enrollment. All laboratory studies will need to be complete within 7 days prior to initiating protocol therapy. All imaging studies will need to be done within 28 days prior to starting treatment.
- •Age: Patients must be > 1 year of age and . 30 years of age at time of initiation of protocol therapy.
- •Diagnosis: Patients have a histologically or radiographically confirmed relapsed or refractory STS.
- •Disease Status: Patients must have evaluable disease.
- •a. Patients may have CNS metastases at study entry, if they are previously treated or stable (defined by not requiring initiation or the need for increased steroids for 7 days).
- •Performance Level: Karnofsky . 50% for patients > 16 years old, and Lansky . 50 for patients 1-16 years old. (See Appendix I)
- •Prior Therapy: Patients may have received prior therapy including single-agent pazopanib or trabectedin. Patients may not have previously been treated with combination therapy of pazopanib and trabectedin.
- •a. Patients must be fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. Delayed toxicities from chemotherapy (e.g. requiring electrolyte replacement, alopecia) will be permitted as long as they are stable or improving and approved by the study PI. i. Hematopoietic growth factor: At least 7 days must have elapsed since the last administration of filgrastim, or 14 days since administration of pegfilgrastim. ii. XRT: At least 7 days since the last dose of local palliative radiation therapy. Greater than 6 months must have elapsed since the last day of treatment if given total body irradiation, craniospinal irradiation. iii. Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft versus host disease and no current need for immunosuppressive medication. Greater than 3 months must have elapsed since engraftment and no longer requiring transfusion of platelets or injection of colony stimulating factors.
- •Organ Function Requirements a. Bone Marrow Function: i. Peripheral absolute neutrophil count (ANC) . 750/ƒÊL ii. Platelet count . 75,000/ƒÊL (no platelet transfusion within 7 days prior to obtaining laboratory result) b. Adequate Renal Function: i. Creatinine clearance or glomerular filtration rate . 70ml/min/1.73m2 (calculated or measured as appropriate for age and level of concern by treating MD) c. Adequate Liver Function: i. Total bilirubin . 1.5x upper limit of normal (ULN) for age ii. SGPT (ALT) . 3 x ULN iii. Serum albumin . 2gm/dL Due to the risk of hepatic injury, including fatal hepatic failure, temozolomide should not be administered if total bilirubin is >2.0 mg/dl or SGPT(ALT)> 3 x ULN.
排除标准
- •Significant organ dysfunction, not meeting inclusion criteria.
- •Pediatric subjects who are considered wards of some entity.
- •Pregnancy or Breast-Feeding Pregnant or breast-feeding woman will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies.
- •Concomitant Medications:
- •Growth factor: Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days.
- •Investigational Drugs: Patients who are currently receiving another investigational drug. (Please refer to section 4.1, Prior Therapy)
- •Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents. (Please refer to section 4.1, Prior Therapy)
- •Medication Allergy:
- •i. Allergy or intolerance to agents on this protocol: Trabectedin. Pazopanib, Ipilimumab or Nivolumab e. Infection: Patients who have uncontrolled infection, positive blood cultures within the past 48 hours, or receiving treatment for Clostridium difficile infection.
- •Known history of human immunodeficiency virus (HIV) infection
- •Known active infection of hepatitis B or Hepatitis C virus
研究组 & 干预措施
Phase I Dose Escalation: Treatment with Pazopanib + Trabectedin + Ipilimumab + Nivolumab
Experimental
Participants will begiven:
- Ipilimumab 1 mg/kg IV q9 weeks
- Trabectedin 1.2 mg/m² IV over 3h q3 weeks
- Nivolumab 3 mg/kg IV q3 weeks
- Pazopanib dose levels
- Escalating Pazopanib x 200mg (100 mg/m2/day for pediatric) PO daily per 7-day intervals until dose level continuation dose.
- For pediatric participants, mg/m2/day dose will be calculated and the lower of fixed versus BSA-based dose will be used
- Given tablet size of 200mg, dosing will be averaged over 7-day period
- 200mg qD x 7d (level 0); 400mg qD (level 1) x 7d; 600mg qD (level 2) x 7d; 800mg qD (level 3)
- 100mg/m2/day 7d (level 0); 200mg/m2/day 7d (level 1), 300mg/m2/day 7d (level 2), 400mg/m2/day (level 3)
- Pre-phase with Trabectedin + Pazopanib & Delay 1st Ipi/Nivo
干预措施: Ipilimumab (Drug)
Phase I Dose Escalation: Treatment with Pazopanib + Trabectedin + Ipilimumab + Nivolumab
Experimental
Participants will begiven:
- Ipilimumab 1 mg/kg IV q9 weeks
- Trabectedin 1.2 mg/m² IV over 3h q3 weeks
- Nivolumab 3 mg/kg IV q3 weeks
- Pazopanib dose levels
- Escalating Pazopanib x 200mg (100 mg/m2/day for pediatric) PO daily per 7-day intervals until dose level continuation dose.
- For pediatric participants, mg/m2/day dose will be calculated and the lower of fixed versus BSA-based dose will be used
- Given tablet size of 200mg, dosing will be averaged over 7-day period
- 200mg qD x 7d (level 0); 400mg qD (level 1) x 7d; 600mg qD (level 2) x 7d; 800mg qD (level 3)
- 100mg/m2/day 7d (level 0); 200mg/m2/day 7d (level 1), 300mg/m2/day 7d (level 2), 400mg/m2/day (level 3)
- Pre-phase with Trabectedin + Pazopanib & Delay 1st Ipi/Nivo
干预措施: Pazopanib (Drug)
Phase I Dose Escalation: Treatment with Pazopanib + Trabectedin + Ipilimumab + Nivolumab
Experimental
Participants will begiven:
- Ipilimumab 1 mg/kg IV q9 weeks
- Trabectedin 1.2 mg/m² IV over 3h q3 weeks
- Nivolumab 3 mg/kg IV q3 weeks
- Pazopanib dose levels
- Escalating Pazopanib x 200mg (100 mg/m2/day for pediatric) PO daily per 7-day intervals until dose level continuation dose.
- For pediatric participants, mg/m2/day dose will be calculated and the lower of fixed versus BSA-based dose will be used
- Given tablet size of 200mg, dosing will be averaged over 7-day period
- 200mg qD x 7d (level 0); 400mg qD (level 1) x 7d; 600mg qD (level 2) x 7d; 800mg qD (level 3)
- 100mg/m2/day 7d (level 0); 200mg/m2/day 7d (level 1), 300mg/m2/day 7d (level 2), 400mg/m2/day (level 3)
- Pre-phase with Trabectedin + Pazopanib & Delay 1st Ipi/Nivo
干预措施: Trabectedin (Drug)
Phase I Dose Escalation: Treatment with Pazopanib + Trabectedin + Ipilimumab + Nivolumab
Experimental
Participants will begiven:
- Ipilimumab 1 mg/kg IV q9 weeks
- Trabectedin 1.2 mg/m² IV over 3h q3 weeks
- Nivolumab 3 mg/kg IV q3 weeks
- Pazopanib dose levels
- Escalating Pazopanib x 200mg (100 mg/m2/day for pediatric) PO daily per 7-day intervals until dose level continuation dose.
- For pediatric participants, mg/m2/day dose will be calculated and the lower of fixed versus BSA-based dose will be used
- Given tablet size of 200mg, dosing will be averaged over 7-day period
- 200mg qD x 7d (level 0); 400mg qD (level 1) x 7d; 600mg qD (level 2) x 7d; 800mg qD (level 3)
- 100mg/m2/day 7d (level 0); 200mg/m2/day 7d (level 1), 300mg/m2/day 7d (level 2), 400mg/m2/day (level 3)
- Pre-phase with Trabectedin + Pazopanib & Delay 1st Ipi/Nivo
干预措施: Nivolumab (Drug)
结局指标
主要结局
Safety and Adverse Events (AEs)
时间窗: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Pacritinib With Aza for Upfront Myelodysplastic SyndromeMDSMyelodysplastic SyndromesMyelodysplastic Syndrome, UnclassifiableHematologic DiseasesBone Marrow DiseaseMyeloproliferative NeoplasmNCT07387354Thomas Jefferson University25
尚未招募
2 期
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant ChemotherapyBreast CancerNCT07410234Tianjin Medical University Cancer Institute and Hospital110
招募中
2 期
A Rollover Study Evaluating Sotorasib with or without Panitumumab in Subjects with KRAS p.G12C Mutation.Advanced solid tumors.2025-522355-26-00Amgen Inc.2
招募中
2 期
Rash & Diarrhea Prophylaxis With CapivasertibMetastatic HR+/HER2- Breast CancerNCT07426822Maryam Lustberg108
招募中
2 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.2024-514058-59-00Fondazione IRCCS Istituto Nazionale Dei Tumori49